AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 161 min read$GKOS

Glaukos (NYSE: GKOS) officer lines up new stock sale after $2.48M August trade

Glaukos (GKOS) officer Tomas Navratil plans to sell 1,457 shares of common stock, tied to restricted stock vesting events in March 2025. The sale is part of a Rule 144 notice, with prior sales also reported. The shares are part of Navratil's compensation.

Original reporting
stocktitan.net
Published Sep 16, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GKOSBearishLow
01

Why it matters

The filing signals a modest increase in supply of GKOS shares, which may slightly depress the stock price in the short term.

02

Market read

A small insider sale with limited market impact; traders may watch for any price reaction but no major trading decision is warranted.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the insider to liquidate shares.

Relevance 4/10Novelty 3/10Timing: recent filing

Background

Form 144 filings disclose planned sales of restricted securities by insiders, providing transparency to investors.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Officer Tomas Navratil filed a Form 144 to sell 1,457 restricted shares, the first public disclosure of this insider sale.

Expected impact

Potential short-term dip of 1‑2% as the market digests the insider sell.

Evidence & confidence

Insider sales of restricted stock are often viewed as a neutral to slightly negative signal, especially when the amount is modest.

Market effects

Sector

Minimal impact on the ophthalmic device sector; no broader industry signal.

Regional

Limited to US markets where GKOS trades.

Global

Low; the filing does not affect global market dynamics.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain stable.

Key entities

  • Officer
    Tomas Navratil

    Glaukos officer filing the insider sale.

  • Company
    Glaukos Corp

    Issuer of the restricted shares being sold.

Read at source← All news

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min